GCM
TBPH icon

Gladius Capital Management’s Theravance Biopharma TBPH Stock Holding History

Gladius Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,190
Closed -$34.6K – 458
2023
Q1 		$34.6K Sell
3,190
-363
-10% -$3.84K ﹤0.01% 260
2022
Q4 		$39.9K Buy
+3,553
New +$37.3K ﹤0.01% 221

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gladius Capital Management's TBPH Position: Q2 2023 in Review

Gladius Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2023, closing a stake of 3,190 shares — an estimated $34.6K sold.

Gladius Capital Management first reported a position in TBPH in Q4 2022 and held it in 2 quarters. The position peaked at $39.9K in Q4 2022. 119 funds tracked by Wall St. Rank hold TBPH as of Q2 2023.

  • Gladius Capital Management reported no remaining Theravance Biopharma position as of Q2 2023 after selling out during the quarter.
  • Gladius Capital Management sold 3,190 Theravance Biopharma shares in Q2 2023, an estimated $34.6K.
  • Gladius Capital Management first reported a position in Theravance Biopharma in Q4 2022 and held it in 2 quarters.
  • Gladius Capital Management's Theravance Biopharma position peaked at $39.9K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2023.

Based on Gladius Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.